5323312025-10-012025-12-315323312025-04-012025-12-315323312025-10-012025-12-31in-capmkt:OtherExpenses1Member5323312025-04-012025-12-31in-capmkt:OtherExpenses1Member5323312025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532331AJANTPHARMNOTLISTEDINE031B01049Ajanta Pharma LimitedMain BoardEquity2025-04-012026-03-312026-01-302026-01-12INRCroresQuarterlyThird quarterSingle segmentPharmacutical2026-01-3013:30:002026-01-3015:00:00Declaration of unmodified opinionfalsefalseNosuchdefault2025-10-012025-12-31UnauditedStandalone12065900000257600000123235000002350700000578900000-3823000003061600000187000004238000003047500000909890000032246000000322460000072580000048400000774200000024504000000000245040000019000002452300000250700000219.6119.610019.6119.611. The above standalone unaudited results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2026. The statutory auditors have expressed an unmodified opinion on the results for the quarter and nine month period ended 31 December 2025. The review report has been filed with the stock exchange and is available on company website. <BR> <BR> 2.Other income / Other expense includes:- Rs in Crore <BR> <BR> Particular Quarter ended Nine Month ended Year ended <BR> 31-Dec-25 30-Set-25 31-Dec-24 31-Dec-25 31-Dec-24 31-Mar-25 <BR> <BR> Dividend from Subsidiaries - 15.21 - 36.68 22.28 22.28 <BR> (in other income) <BR> Foreign exchange gain 9.42 41.52 20.72 53.50 30.73 32.96 <BR> (in other income) <BR> Foreign exchange loss - 40.95 - 61.34 13.88 8.82 <BR> (in other expenses) <BR> <BR> 3. During nine month ended 31 December 2025, 23,525 (previous year 25,325) equity shares of Rs 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by Rs 47,050 (previous year Rs 50,650) and securities premium by Rs 3.50 crores (previous year Rs 3.84 crores).Under the same plan, 4,300 Cash Settled Stock Appreciation Rights (SARs) are being vested and will be settled in cash. Hence, there will not be any change in the paid-up share capital and securities premium of the company on account of SARs. <BR> <BR> 4. In August 2025, the Income Tax Authorities carried out search operations at certain premises of the Company. The Company has not yet received any formal communication from the Income Tax Authorities in this regard and hence no adjustments have been made in the standalone financial results for the quarter and period ended 31 December 2025. <BR> <BR> 5. The Government of India has announced four Labour Code and have made them effective from 21st November, 2025. The corresponding all supporting rules under these codes are yet to be notified. The company is in the process of evaluating the full impact of these new labour codes announced. The company has estimated and accounted for incremental liability for own employees and the Company continues to monitor the finalisation of Central/State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. <BR> <BR> 6.The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals". <BR> <BR> 7. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com. <BR> 2025-04-012025-12-31UnauditedStandalone3635390000014142000003776810000065975000001600700000-776000008805600000333000001246100000982830000028033900000973420000009734200000209280000014600000022388000000749540000000007495400000-25900000746950000025070000026059.99006059.99Other Expenses3047500000Other Expenses9828300000Re-measurement of defined benefit liability/(assets)28000002800000Re-measurement of defined benefit liability/(assets)-39900000-39900000900000-14000000001900000-25900000UnauditedtrueB S R & Co. LLPtrue2025-07-31